Nectar Lifesciences
Nectar Lifesciences Share Price Chart
Nectar Lifesciences last traded at ₹10.16 (2026-10-13). Over the past month the stock moved -14.7%, three months the stock moved -16.7%, year the stock moved -36.7%. Its closing range over 52 weeks is ₹9.79 – ₹21.80, with the latest close 53.4% below the high.
Closing prices up to 2026-10-13.
About Nectar Lifesciences
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]
Business Overview:[1] NLL is a research-driven manufacturer of Active Pharmaceutical Ingredients, intermediates, and finished dosage forms, specializing in anti-infectives like Cephalosporins. It also serves as a CMO for global pharma innovators.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Nectar Lifesciences reported sales of ₹0.00 crore (-100.0%) and net profit of ₹-15.00 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 0.00 | -27.00 | -6,198.00 | -15.00 | -0.79 |
| Mar 2026 | 1.00 | -57.00 | -4,437.00 | -68.00 | -3.50 |
| Dec 2025 | 0.00 | -2.00 | – | 14.00 | 0.64 |
| Sep 2025 | 1.00 | 1.00 | 77.00 | -176.00 | -7.85 |
| Jun 2025 | 5.00 | -1.00 | -16.00 | -63.00 | -2.82 |
| Mar 2025 | 0.00 | 0.00 | -500.00 | -130.00 | -5.80 |
| Dec 2024 | 0.00 | 0.00 | -500.00 | 8.00 | 0.35 |
| Sep 2024 | 6.00 | -1.00 | -10.00 | 6.00 | 0.25 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -98.5% | -100.0% | -100.0% | -98.6% | -83.3% | – | – | -100.0% |
| Operating profit growth | -103.7% | -100.0% | -100.0% | -102.5% | – | – | – | – |
| Net profit growth | +500.0% | +300.0% | -13100.0% | -2200.0% | -3033.3% | +75.0% | – | – |
| EPS growth | +400.0% | +400.0% | -19433.3% | -2269.2% | -3240.0% | +82.9% | – | – |
| OPM % | -10.0% | -500.0% | -500.0% | -16.0% | 77.0% | – | -4437.0% | -6198.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Nectar Lifesciences reported sales of ₹2.00 crore (-99.9%) and net profit of ₹-293.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 2.00 | -59.00 | -2,920.00 | -293.00 | -15.08 |
| Mar 2025 | 1,673 | -26.00 | -2.00 | -114.00 | -5.07 |
| Mar 2024 | 1,682 | 152.00 | 9.00 | 5.00 | 0.22 |
| Mar 2023 | 1,520 | 53.00 | 3.00 | -24.00 | -1.08 |
| Mar 2022 | 1,665 | 159.00 | 10.00 | 25.00 | 1.12 |
| Mar 2021 | 1,541 | 109.00 | 7.00 | -73.00 | -3.27 |
| Mar 2020 | 2,363 | 220.00 | 9.00 | 32.00 | 1.42 |
| Mar 2019 | 2,779 | 264.00 | 10.00 | 48.00 | 2.12 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +48.3% | -15.0% | -34.8% | +8.0% | -8.7% | +10.7% | -0.5% | -99.9% |
| Operating profit growth | +11.9% | -16.7% | -50.5% | +45.9% | -66.7% | +186.8% | -117.1% | – |
| Net profit growth | -7.7% | -33.3% | -328.1% | – | -196.0% | – | -2380.0% | – |
| EPS growth | -9.0% | -33.0% | -330.3% | – | -196.4% | – | -2404.5% | – |
| OPM % | 10.0% | 9.0% | 7.0% | 10.0% | 3.0% | 9.0% | -2.0% | -2920.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Nectar Lifesciences.
Get Free AI Stock Analysis FREE →Latest News
-
Nectar Lifesciences AGM: Shareholders approve FY26 financials, board appointments - scanx.trade
-
Nectar Lifesciences AGM: Shareholders approve FY26 financials, board appointments - scanx.trade
-
Nectar Lifesciences schedules 31st AGM for September 18, 2026 - scanx.trade
-
Nectar Lifesciences extends slump sale completion to Dec 31, 2026 - scanx.trade
-
Nectar Lifesciences gets nod to acquire 100% stake in Avensis Export
-
Nectar Lifesciences completes sale of API and formulations business
Frequently Asked Questions
What is Nectar Lifesciences's current stock price?
Nectar Lifesciences shares were last quoted at ₹10.16 (+0.3% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Nectar Lifesciences?
Nectar Lifesciences has a price-to-earnings (P/E) ratio of -0.99 and a price-to-book (P/B) ratio of 0.42. The industry P/E is 53.33.
What is the 52-week high and low of Nectar Lifesciences?
The 52-week high of Nectar Lifesciences is ₹22.49 and the 52-week low is ₹9.20.
What is the market cap of Nectar Lifesciences?
The market capitalisation of Nectar Lifesciences is about ₹241.53 crore.
How did Nectar Lifesciences perform in its latest quarterly results?
In the latest quarter (Jun 2026), Nectar Lifesciences reported sales of ₹0.00 crore (-100.0%) and net profit of ₹-15.00 crore, compared with the same quarter last year.
Is Nectar Lifesciences a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Nectar Lifesciences has a 3-year ROE of -6.00%, 3-year profit growth of 4.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Nectar Lifesciences?
Promoters hold about 51.84% of Nectar Lifesciences.
Which sector does Nectar Lifesciences belong to?
Nectar Lifesciences belongs to the Pharmaceuticals & Drugs sector.